Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (PASSAGE)

AstraZeneca logo

AstraZeneca

Status and phase

Enrolling
Phase 4

Conditions

Asthma

Treatments

Drug: Tezepelumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT05329194
D5180C00032

Details and patient eligibility

About

To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.

Full description

This is a multicenter, single-arm, open-label, Post-authorization, Phase 4 study to assess the effectiveness of tezepelumab in the United States (US) among a real-world population of adults and adolescent participants with asthma requiring medium-dose to high-dose inhaled corticosteroids (ICS), with additional controller(s) for at least 12 months with documented history of at least 2 asthma exacerbations during the year prior to enrolment. The total duration of the study for each participant will be approximately 56 weeks. Approximately 400 participants will be enrolled. Participants will receive tezepelumab via subcutaneous injection at the study site, over a 48-week treatment period. The study also includes a post-dosing follow-up period from Weeks 48 to 52.

Enrollment

400 estimated patients

Sex

All

Ages

12 to 130 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Male or female participant must be 12 years of age or older, at the time of signing the informed consent form or assent. * Documented physician-diagnosed asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses. * Documented treatment with medium- to high dose ICS as per Global Initiative for Asthma (GINA) guidelines (GINA 2021) for at least 12 months prior to enrollment. * Use of additional asthma maintenance controller medication(s) in addition to ICS for at least 12 months prior to enrollment. The additional maintenance controller medication may be contained in a combination product (eg, ICS/ long-acting β-agonist (LABA)). * Documented history of at least 2 asthma exacerbations during the 12 months prior to enrollment. * Physician decision that participant is eligible for treatment with tezepelumab according to the approved United States product insert (USPI). * Currently receiving care from specialist physicians (eg, pulmonologists and/or allergists). * Provision of signed and dated written informed consent form.

Exclusion criteria

* Any contraindication to tezepelumab as per the US approved product label or in the opinion of the Investigator. * Comorbid diagnosis of severe or very severe chronic obstructive pulmonary disease (COPD) per GOLD guidelines (GOLD 2021). * Use of biologics that are approved for the treatment of asthma within 4 months or 5 half- lives (whichever is longer) prior to enrollment. * Participation in an interventional clinical trial for asthma within 12 months prior to enrollment. * Judgment by the Investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

400 participants in 1 patient group

Tezepelumab
Experimental group
Description:
Participants will be receiving 210 mg of tezepelumab every 4 weeks (Q4W) from Week 0 until Week 48.
Treatment:
Drug: Tezepelumab

Trial contacts and locations

45

Loading...

Central trial contact

AstraZeneca Clinical Study Information Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems